This is the case of follitropin delta that resulted, notwithstanding the lack of type A evidence, an effective treatment in terms of reduction of early OHSS risk in GnRH antagonist IVF/ICSI cycles with potentially better reproductive outcomes when compared with follitropin alfa [11]. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.